Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
ACAD ACADIA Pharmaceuticals Inc. daily Stock Chart
ACAD [NASD]
ACADIA Pharmaceuticals Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E- EPS (ttm)-1.60 Insider Own0.09% Shs Outstand158.85M Perf Week9.02%
Market Cap6.80B Forward P/E- EPS next Y-0.29 Insider Trans395.61% Shs Float155.19M Perf Month4.36%
Income-235.30M PEG- EPS next Q-0.47 Inst Own96.80% Short Float7.81% Perf Quarter-3.63%
Sales339.10M P/S20.05 EPS this Y17.50% Inst Trans0.05% Short Ratio8.62 Perf Half Y9.55%
Book/sh4.52 P/B9.47 EPS next Y84.50% ROA-37.50% Target Price57.81 Perf Year60.48%
Cash/sh4.39 P/C9.75 EPS next 5Y25.00% ROE-42.90% 52W Range21.56 - 53.70 Perf YTD0.05%
Dividend- P/FCF- EPS past 5Y-10.90% ROI-35.40% 52W High-20.30% Beta1.94
Dividend %- Quick Ratio10.10 Sales past 5Y390.00% Gross Margin94.20% 52W Low98.52% ATR3.20
Employees501 Current Ratio10.20 Sales Q/Q64.90% Oper. Margin-72.70% RSI (14)56.17 Volatility6.81% 9.44%
OptionableYes Debt/Eq0.00 EPS Q/Q31.00% Profit Margin-69.40% Rel Volume0.73 Prev Close41.71
ShortableYes LT Debt/Eq0.00 EarningsFeb 26 AMC Payout- Avg Volume1.41M Price42.80
Recom1.80 SMA2013.38% SMA505.20% SMA20012.39% Volume1,059,486 Change2.61%
Mar-31-20Upgrade Goldman Neutral → Buy $45 → $72
Mar-06-20Initiated Citigroup Buy $69
Dec-16-19Initiated Guggenheim Buy $60
Oct-24-19Initiated Oppenheimer Perform $44
Oct-01-19Initiated RBC Capital Mkts Outperform $60
Sep-13-19Upgrade SVB Leerink Mkt Perform → Outperform
Sep-10-19Upgrade Canaccord Genuity Hold → Buy $29 → $50
Jul-23-19Reiterated Needham Buy $40 → $34
Dec-10-18Initiated Canaccord Genuity Hold $23
Sep-21-18Upgrade Piper Jaffray Neutral → Overweight
Aug-09-18Reiterated Stifel Hold $17 → $14
Aug-07-18Initiated Stifel Hold $17
Aug-06-18Downgrade Piper Jaffray Overweight → Neutral
Oct-06-17Resumed Goldman Neutral
Nov-11-16Initiated Goldman Neutral
Nov-08-16Upgrade BofA/Merrill Neutral → Buy
Oct-19-16Resumed ROTH Capital Neutral
Oct-04-16Initiated Leerink Partners Mkt Perform $34
Jun-22-16Downgrade BofA/Merrill Buy → Neutral
May-03-16Downgrade Leerink Partners Outperform → Mkt Perform
Mar-27-20 11:31AM  Why Is Acadia (ACAD) Up 1.1% Since Last Earnings Report? Zacks
Mar-24-20 04:23PM  Biotech stocks have held up better than the broader market and these five are potential winners MarketWatch +8.74%
Mar-22-20 05:04PM  Largest Insider Trades of the Week GuruFocus.com
Mar-20-20 02:11PM  Hedge Funds Have Never Been This Bullish On ACADIA Pharmaceuticals Inc. (ACAD) Insider Monkey
Mar-17-20 12:06AM  Edited Transcript of ACAD earnings conference call or presentation 26-Feb-20 10:00pm GMT Thomson Reuters StreetEvents +8.63%
Mar-03-20 05:50PM  ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Rare Pediatric Disease Designation for Trofinetide for the Treatment of Rett Syndrome Business Wire
Feb-28-20 08:35PM  Dont Expect Virgin Galactic Shares to Keep Rocketing Upward Barrons.com +9.31%
01:54PM  ACADIA Pharmaceuticals Inc. Just Released Its Yearly Results And Analysts Are Updating Their Estimates Simply Wall St.
Feb-27-20 11:13AM  ACADIA (ACAD) Q4 Earnings Surpass, Nuplazid Drives Sales Zacks
Feb-26-20 05:35PM  Acadia Pharmaceuticals (ACAD) Reports Q4 Loss, Tops Revenue Estimates Zacks
04:05PM  ACADIA Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results Business Wire
Feb-24-20 09:00AM  ACADIA Pharmaceuticals to Present at the Cowen and Company 40th Annual Health Care Conference on March 2, 2020 Business Wire -6.38%
Feb-19-20 12:31PM  Acadia Pharmaceuticals (ACAD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Feb-12-20 09:00AM  ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results on February 26, 2020 Business Wire
Feb-05-20 06:13AM  Analysts Expect Breakeven For ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Simply Wall St.
Jan-29-20 05:00AM  ACADIA- From Depression to Schizophrenia MoneyShow
Jan-17-20 08:45AM  ACADIA (ACAD) Up More Than 100% in the Past Year: Here's Why Zacks
Jan-10-20 11:54AM  How Did ACADIA Pharmaceuticals Inc. (ACAD) Perform In Comparison to Hedge Fund Favorites in 2019? Insider Monkey
Jan-07-20 09:00AM  ACADIA Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference on January 14, 2020 Business Wire
Dec-23-19 02:47PM  Investors flock to neuro drug makers after FDA approves new schizophrenia drug MarketWatch
11:30AM  Has ACADIA Pharmaceuticals (ACAD) Outpaced Other Medical Stocks This Year? Zacks
Dec-22-19 07:12AM  Can You Imagine How Chuffed ACADIA Pharmaceuticals's (NASDAQ:ACAD) Shareholders Feel About Its 215% Share Price Gain? Simply Wall St.
Dec-19-19 10:18AM  Biotech Stock Outlook: M&A Activity Retains Growth Streak Zacks
Dec-18-19 04:05PM  ACADIA Pharmaceuticals Appoints Stephanie Fagan as Senior Vice President, Corporate Affairs and Chief Communications Officer Business Wire -5.81%
Dec-17-19 09:11AM  5 Biotech Stocks That Have More Than Doubled This Year Zacks
Dec-12-19 11:56AM  The Zacks Analyst Blog Highlights: ACADIA, Compugen, Cue Biopharma, Epizyme and Krystal Biotech Zacks
Dec-11-19 09:04AM  5 Biotech Stocks Up More Than 100% This Year So Far Zacks
Dec-06-19 07:39AM  The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes Dividend Benzinga
05:00AM  A 60% Tumble for Sage Therapeutics, and Two More Numbers to Know Barrons.com
Dec-05-19 11:01PM  Hedge Funds Snapped Up ACADIA Pharmaceuticals Inc. (ACAD) Before The Q4 Rally Insider Monkey +14.00%
04:08PM  Why This Highflying Biotech Stock Zoomed Near A Profit-Taking Zone Investor's Business Daily
10:08AM  Biotech Stocks Are Making Wild Moves Amid a Deluge of Trial Data Barrons.com
07:14AM  The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission Benzinga
Dec-04-19 08:45PM  Acadia Pharma's psychosis drug proven better than placebo in dementia patients Reuters
08:45PM  ACADIA Pharmaceuticals Presents Positive Top-line Results from Pivotal Phase 3 HARMONY Trial of Pimavanserin in Patients with Dementia-Related Psychosis at 12th Clinical Trials on Alzheimers Disease (CTAD) Meeting Business Wire
Dec-02-19 02:57PM  7 Exciting Biotech Stocks to Buy Now InvestorPlace
Dec-01-19 09:30AM  The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More Benzinga
07:27AM  3 Monster Growth Stocks That Are Still in the Buy Zone TipRanks
Nov-27-19 10:00AM  What Makes Acadia Pharmaceuticals (ACAD) a Strong Momentum Stock: Buy Now? Zacks
Nov-25-19 04:03PM  ACADIA Pharmaceuticals Announces Positive Top-line Results from ADVANCE Trial of Pimavanserin as Treatment for Negative Symptoms of Schizophrenia Business Wire
08:58AM  Top Ranked Momentum Stocks to Buy for November 25th Zacks
Nov-21-19 09:56AM  The Medicines Company Soars Amid Acquisition Whispers Investopedia
Nov-18-19 10:17AM  Medtronic (MDT) to Report Q2 Earnings: What's in Store? Zacks
Nov-12-19 08:18AM  The Zacks Analyst Blog Highlights: Coherus, Incyte, ACADIA and Celgene Zacks
Nov-11-19 04:48PM  IBD Stock Of The Day Breaks Out As It Stares Down A Massive Opportunity Investor's Business Daily +6.17%
09:28AM  4 Biotech Stocks That Could Keep Beating Wall Street Zacks
09:00AM  ACADIA Pharmaceuticals to Host Investor Event and Webcast From Clinical Trials on Alzheimers Disease (CTAD) Meeting on December 4, 2019 Business Wire
Nov-07-19 05:13AM  Have Insiders Been Selling ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Shares? Simply Wall St.
Nov-06-19 10:00AM  What Makes Acadia Pharmaceuticals (ACAD) a Strong Momentum Stock: Buy Now? Zacks
09:00AM  Acadia (ACAD) Upgraded to Buy: Here's Why Zacks
Nov-04-19 05:40PM  Edited Transcript of ACAD earnings conference call or presentation 30-Oct-19 8:30pm GMT Thomson Reuters StreetEvents
09:00AM  ACADIA Pharmaceuticals Appoints Ponni Subbiah, M.D., M.P.H., as Senior Vice President, Global Head of Medical Affairs and Chief Medical Officer Business Wire
Oct-30-19 07:25PM  Acadia Pharmaceuticals (ACAD) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:15PM  ACADIA Pharmaceuticals Initiates Phase 3 Pivotal Study of Trofinetide in Rett Syndrome, a Rare Neurodevelopmental Congenital CNS Disorder Business Wire
04:05PM  ACADIA Pharmaceuticals Reports Third Quarter 2019 Financial Results Business Wire
Oct-29-19 08:46AM  Cigna (CI) to Report Q3 Earnings: What's in the Offing? Zacks
Oct-28-19 11:22AM  Teladoc (TDOC) to Report Q3 Earnings: What's in the Cards? Zacks
Oct-25-19 12:12PM  Will Nuplazid Aid Growth for ACADIA (ACAD) in Q3 Earnings? Zacks
Oct-24-19 04:58PM  Hedge Funds Are Betting On ACADIA Pharmaceuticals Inc. (ACAD) Again Insider Monkey
Oct-23-19 10:33AM  Acadia Pharmaceuticals (ACAD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Oct-16-19 09:00AM  ACADIA Pharmaceuticals to Announce Third Quarter 2019 Financial Results on October 30, 2019 Business Wire
Oct-09-19 11:18AM  Biotech Stock Roundup: GILD's Descovy Label Expansion Gets FDA Nod & Other Updates Zacks
Oct-08-19 06:00AM  Acadia Sees Strong Results in Dementia Treatment MoneyShow
Oct-07-19 09:00AM  ACADIA Pharmaceuticals Presents Additional Positive Data from the Phase 2 CLARITY Study with Pimavanserin in Adjunctive Major Depressive Disorder at 2019 Psych Congress Business Wire
Oct-03-19 04:55PM  ACADIA Pharmaceuticals Announces Late-Breaking Oral Presentation of the Phase 3 HARMONY Study of Pimavanserin in Dementia-Related Psychosis at the Clinical Trials on Alzheimers Disease (CTAD) 2019 Meeting Business Wire
Oct-02-19 06:37AM  We Think ACADIA Pharmaceuticals (NASDAQ:ACAD) Can Easily Afford To Drive Business Growth Simply Wall St.
Sep-26-19 09:14AM  Should First Trust Mid Cap Growth AlphaDEX Fund (FNY) Be on Your Investing Radar? Zacks
Sep-25-19 04:05PM  ACADIA Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference on October 2, 2019 Business Wire
Sep-24-19 04:05PM  ACADIA Pharmaceuticals Announces that The Journal of Clinical Psychiatry Publishes Positive Phase 2 CLARITY Results for Pimavanserin as Adjunctive Treatment for Patients with Major Depressive Disorder Business Wire -7.07%
Sep-23-19 09:00AM  ACADIA Pharmaceuticals Presents New Data on PD Patients Treated with Pimavanserin for Depression at the 2019 International Congress of Parkinsons Disease and Movement Disorders Business Wire
Sep-20-19 04:05PM  ACADIA Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares Business Wire
01:10PM  Gilead, AbbVie Are Innovative, but May Be Underappreciated GuruFocus.com
Sep-19-19 09:00AM  ACADIA Pharmaceuticals to Present New Clinical Data and Outcomes Research at Upcoming Scientific Meetings Business Wire
Sep-17-19 11:00PM  ACADIA Pharmaceuticals Prices Public Offering of Common Stock Business Wire
04:02PM  ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock Business Wire
03:25PM  5 Top Stock Trades for Wednesday: BA, ACB, PINS InvestorPlace
Sep-11-19 10:23AM  3 Hot Biotechs with High Upside Potential TipRanks
Sep-10-19 01:20PM  'Pleasantly Surprised' Acadia Analysts See Blockbuster Potential For Pimavanserin In Dementia Psychosis Benzinga +6.10%
11:41AM  ACADIA Surges on Early Success of Nuplazid Dementia Study Zacks
10:59AM  Will ACADIA Continue to Surge Higher? Zacks
08:39AM  Is Acadia Pharmaceuticals a Good Biotech Stock to Buy Now? Motley Fool
07:36AM  The Daily Biotech Pulse: Translate Bio Halts mRNA Therapy Trial, Roche Multiple Sclerosis Biomarker Data, D-Day For Xeris Benzinga
Sep-09-19 05:38PM  Why Acadia Pharmaceuticals Stock Skyrocketed Today Motley Fool +63.24%
04:55PM  ACADIA Pharmaceuticals Help Lift Biotech ETFs ETF Trends
04:26PM  Why This Biotech Stock Just Rocketed 63% After Hitting A 4-Year High Investor's Business Daily
04:13PM  What Happened in the Stock Market Today Motley Fool
02:33PM  Acadia Stops Nuplazid Study Early After Drug Shows 'Statistically Superior Efficacy' In Dementia-Related Psychosis Benzinga
12:17PM  A Look At Benzinga Pro's Most-Searched Tickers For September 9, 2019 Benzinga
10:26AM  Options Hot as ACADIA Pharmaceuticals Stock Soars Schaeffer's Investment Research
09:05AM  ACADIA Enters Oversold Territory Zacks
07:31AM  [video]Acadia Pharmaceuticals Surges on Positive Trial Results for Psychosis Treatment TheStreet.com
07:26AM  Acadia Pharmaceuticals stock rockets after late-stage trial of pimavanserin mets primary endpoint MarketWatch
06:30AM  ACADIA Pharmaceuticals Announces Pivotal Phase 3 HARMONY Trial Stopped Early for Positive Efficacy as Pimavanserin Meets the Primary Endpoint in Patients with Dementia-Related Psychosis Business Wire
Sep-04-19 09:00AM  ACADIA Pharmaceuticals to Present at the Morgan Stanley 17th Annual Global Healthcare Conference on September 11, 2019 Business Wire
Aug-29-19 12:47PM  Top Ranked Momentum Stocks to Buy for August 29th Zacks
Aug-27-19 10:29AM  Is There An Opportunity With ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) 37% Undervaluation? Simply Wall St.
Aug-26-19 08:39AM  Top Ranked Momentum Stocks to Buy for August 26th Zacks
Aug-23-19 11:44AM  Top Ranked Momentum Stocks to Buy for August 23rd Zacks
Aug-20-19 08:34AM  Vanda Receives CRL From FDA for sNDA of Jet Lag Treatment Zacks
Aug-16-19 10:42AM  Palatin's (PTN) to Report Q4 Earnings: What's in the Cards? Zacks
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in Phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BAKER BROS. ADVISORS LPDirectorMar 18Buy33.52135,8974,555,10138,433,977Mar 18 06:47 PM
BAKER BROS. ADVISORS LPDirectorMar 17Buy32.84219,8007,218,90738,309,339Mar 18 06:47 PM
BAKER BROS. ADVISORS LPDirectorMar 16Buy31.51694,30321,878,01738,107,749Mar 18 06:47 PM
Brege LauraDirectorJan 07Option Exercise1.7510,00017,50010,000Jan 08 06:01 PM
Brege LauraDirectorJan 07Sale42.1910,000421,9000Jan 08 06:01 PM
YANG MICHAEL J.EVP and CCODec 12Option Exercise31.09105,4793,279,377107,978Dec 13 05:35 PM
YANG MICHAEL J.EVP and CCODec 12Sale44.46105,4794,689,2632,499Dec 13 05:35 PM
KIM AUSTIN D.EVP & General CounselDec 11Option Exercise17.5817,500307,65018,009Dec 13 05:34 PM
KIM AUSTIN D.EVP & General CounselDec 11Sale45.0617,500788,576509Dec 13 05:34 PM
Ridloff ElenaEVP and CFODec 09Option Exercise15.8136,000569,16036,000Dec 11 06:29 PM
YANG MICHAEL J.EVP and CCODec 09Option Exercise35.8614,521520,72316,144Dec 11 06:30 PM
YANG MICHAEL J.EVP and CCODec 09Sale50.4614,521732,7921,623Dec 11 06:30 PM
Ridloff ElenaEVP and CFODec 09Sale49.6636,0001,787,8530Dec 11 06:29 PM
DAVIS STEPHENCEODec 05Option Exercise19.65150,0002,947,500152,954Dec 06 06:25 PM
DAVIS STEPHENCEODec 05Sale52.34150,0007,851,3002,954Dec 06 06:25 PM
Stankovic Srdjan R.PresidentNov 19Sale46.412,160100,2466,027Nov 21 05:37 PM
Miller Eric AlejandroController & PAOOct 15Sale39.651475,829270Oct 17 06:26 PM
YANG MICHAEL J.EVP and CCOOct 15Sale39.6587734,7731,623Oct 17 06:25 PM
Stankovic Srdjan R.PresidentOct 15Sale39.651,03140,8791,937Oct 17 06:24 PM
DAVIS STEPHENCEOOct 15Sale39.652,983118,2762,954Oct 17 06:23 PM
DAVIS STEPHENCEOOct 10Option Exercise19.65120,2082,362,087120,208Oct 11 05:39 PM
DAVIS STEPHENCEOOct 10Sale40.19120,2084,831,0390Oct 11 05:39 PM
DAVIS STEPHENCEOOct 09Option Exercise19.6529,792585,41329,792Oct 11 05:39 PM
DAVIS STEPHENCEOOct 09Sale40.0029,7921,191,7100Oct 11 05:39 PM
BAKER BROS. ADVISORS LPDirectorSep 20Buy40.001,562,50062,500,00037,470,965Sep 20 04:28 PM
Miller Eric AlejandroController & PAOSep 11Sale41.184,645191,2810Sep 11 07:19 PM
Daly James MDirectorSep 09Option Exercise17.5230,000525,60030,000Sep 11 07:18 PM
Miller Eric AlejandroController & PAOSep 09Option Exercise28.7128,467817,21833,112Sep 11 07:19 PM
Miller Eric AlejandroController & PAOSep 09Sale39.4928,4671,124,1624,645Sep 11 07:19 PM
Daly James MDirectorSep 09Sale37.8030,0001,133,8600Sep 11 07:18 PM
open in yahoo | open in reuters | open in google